Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, SE-141 86 Stockholm, Sweden.
Eur J Clin Pharmacol. 2013 May;69 Suppl 1:73-8. doi: 10.1007/s00228-013-1497-5. Epub 2013 May 3.
In September 2012 an interactive course on the "Interface Management of Pharmacotherapy" was organized by the Stockholm Drug and Therapeutics Committee in cooperation with Department of Clinical Pharmacology at Karolinska Institutet and at Karolinska University Hospital in Stockholm, Sweden, in collaboration with the WHO. The basis for the course was the "Stockholm model" for the rational use of medicines but also contained presentations about successful models in interface management of pharmacotherapy in other European countries.
The "Stockholm model" consists of 8 components: 1) Independent Drug and Therapeutics Committee with key role for respected drug experts with policy for "interest of conflicts", 2) The "Wise List", recommendations of medicines jointly for primary and hospital care, 3) Communication strategy with continuous medical education, 4) Systematic introduction of new expensive medicines, 5) E-pharmacological support at "point of care", 6) Methods and tools for follow-up of medicines use, 7) Medicines policy strategy and 8) Operative resources.
The course highlighted the importance of efficient and targeted communication of drug recommendations building on trust among prescribers and patients for the guidelines to achieve high adherence. Trust is achieved by independent Drug and Therapeutics Committees with a key role for respected experts and a strict policy for "conflicts of interest". Representations of GPs are also crucial for successful implementation, being the link between evidence based medicine and practice.
The successful models in Scotland and in Stockholm as well as the ongoing work in Catalonia were considered as examples of multifaceted approaches to improve the quality of medicine use across primary and hospital care.
2012 年 9 月，斯德哥尔摩药物和治疗委员会与卡罗林斯卡研究所临床药理学系以及瑞典斯德哥尔摩卡罗林斯卡大学医院合作，并与世界卫生组织合作，组织了一次关于“药物治疗的界面管理”的互动课程。该课程的基础是合理用药的“斯德哥尔摩模式”，但也包含了其他欧洲国家在药物治疗界面管理方面成功模式的介绍。
“斯德哥尔摩模式”由 8 个部分组成：1）独立的药物和治疗委员会，其关键角色是具有“利益冲突”政策的受尊敬的药物专家，2）“明智清单”，共同为初级保健和医院护理推荐药物，3）持续医学教育的沟通策略，4）新昂贵药物的系统引入，5）“护理点”的电子药理学支持，6）药物使用监测的方法和工具，7）药物政策策略和 8）运作资源。
该课程强调了在处方者和患者之间建立基于信任的高效和有针对性的药物推荐沟通的重要性，这对于指南实现高依从性至关重要。信任是通过独立的药物和治疗委员会实现的，该委员会的关键角色是受尊敬的专家，以及严格的“利益冲突”政策。全科医生的代表也至关重要，因为他们是循证医学和实践之间的联系，是成功实施的关键。
苏格兰和斯德哥尔摩的成功模式以及加泰罗尼亚正在进行的工作被认为是改善初级保健和医院护理中药物使用质量的多方面方法的范例。
